Suppr超能文献

对于门静脉完全闭塞的局部晚期胰腺癌,先进行新辅助化疗,然后在术前经皮肝穿门静脉支架置入术后行全胰切除术加脾切除术及联合血管切除。

Neoadjuvant chemotherapy followed by total pancreatectomy with splenectomy and combined vascular resections after preoperative percutaneous transhepatic portal vein stent placement in locally advanced pancreatic cancer with portal vein total obliteration.

作者信息

Kook Yoonwon, Choi Munseok, Park Jung Yup, Chung Yong Eun, Kim Man-Deuk, Lee Woo Jung, Kang Chang Moo

机构信息

Division of HBP Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, Korea.

出版信息

Ann Hepatobiliary Pancreat Surg. 2020 Nov 30;24(4):551-556. doi: 10.14701/ahbps.2020.24.4.551.

Abstract

Pancreatic cancer is one of the most lethal malignant diseases in gastrointestinal system that only about 15-20% of the patients are potential candidates for resection at diagnostic stage. However, with the advent of neoadjuvant chemotherapy and advancement of surgical skills, patients with locally advanced pancreatic cancer (LAPC), which were deemed initially unresectable, have undergone margin negative radical resection. Here, we present a case of a patient with LAPC who was previously treated with neoadjuvant FOLFIRINOX and underwent pancreaticoduodenectomy combined with vascular resection after preoperative percutaneous transhepatic portal vein stent placement to relieve of portal vein obliteration. The patient recovered without any complication and was discharged on day 8 postoperatively.

摘要

胰腺癌是消化系统中最致命的恶性疾病之一,在诊断阶段只有约15%-20%的患者有手术切除的可能。然而,随着新辅助化疗的出现和手术技术的进步,最初被认为无法切除的局部晚期胰腺癌(LAPC)患者已能接受切缘阴性的根治性切除。在此,我们报告一例LAPC患者,该患者先前接受了新辅助FOLFIRINOX治疗,并在术前经皮经肝门静脉支架置入以缓解门静脉闭塞后,接受了胰十二指肠切除术联合血管切除。患者恢复良好,无任何并发症,术后第8天出院。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/7691189/c9a5e04a371b/AHBPS-24-551-f001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验